+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Occurrence of antibodies to L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls



Occurrence of antibodies to L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls



International Journal of Cancer 48(5): 682-688



Sera from 118 women of 33 to over 90 years of age, with or without a history of cervical squamous-cell carcinoma, were examined for the presence of antibodies to HPV-6b, HPV-16 and HPV-18, L1, L2, E4, and E7 gene products by the use of bacterially derived beta-Gal fusion proteins and Western-blot analysis. Among the cervical cancer patients, 29/46 (63.0%) were positive for antibodies to E4 and/or E7 of HPV-16 and/or E7 of HPV-18. In contrast, only 2 of 31 (6.5%) non-genital cancer patients and 4 of 41 (9.8%) healthy individuals were antibody-positive for HPV-16 E4 or E7, while antibodies to the homologous proteins of HPV-18 could not be detected. Prevalence rates of antibodies to the HPV-16/18 late proteins were 25/46 (54.3%) in the cervical carcinoma group, 13/31 (41.9%) among women with non-genital cancer types, and 18/41 (43.9%) among normal, healthy individuals. Antibodies to HPV-6b late gene products ranged between 6.5% and 12.2% in the different patient groups. Antibodies to HPV-6b E4 and E7 were detected only once. By studying an additional control group of 207 women with a different age distribution, age-dependence of antibodies to HPV gene products could be ruled out. Whereas antibodies to late proteins may indicate that, regardless of clinical stage, HPV infections are wide-spread among the female population, the striking difference between the prevalence rates of antibodies to early proteins of HPV-16 and HPV-18 among cervical cancer patients and controls (p less than 0.001) supports the idea of the involvement of these virus types in carcinogenesis of the cervix.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040849730

Download citation: RISBibTeXText

PMID: 1649138

DOI: 10.1002/ijc.2910480509


Related references

Detection of antibodies to LI, L2, and E4 gene products of human papillomavirus types 6, 11, and 16 among HPV infected patients and controls. Stanley, M A Immunology of human papillomaviruses 109-111, 1994

Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Research 50(24): 7815-7819, 1990

Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls. Tohoku Journal of Experimental Medicine 170(2): 113-121, 1993

Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. Journal of Infectious Diseases 170(6): 1424-1431, 1994

Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. International Journal of Cancer 85(3): 313-318, Feb 1, 2000

Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstetrics & Gynecology 95(1): 134-140, 2000

Association Between Dqb1 and Cervical Cancer in Patients With Human Papillomavirus and Family Controls. Obstetrics & Gynecology 95(1): 134-140, 2000

Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. Journal of Infectious Diseases 172(1): 19-24, 1995

Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer. Clinics 68(6): 809-814, 2014

Detection of E2 gene polymorphism of human papillomavirus type 16 in patients with cervical lesions and cervical cancer. Nan Fang Yi Ke Da Xue Xue Bao 32(10): 1503-1506, 2013

AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 71(4): 465-488, 2011

Detection of human papillomavirus DNA, serum p53, and p53 antibodies in patients with cervical cancer. Journal of Environmental Pathology, Toxicology and Oncology 21(1): 79-85, 2002

Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiology, Biomarkers and Prevention 18(1): 113-120, 2009

Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiology, Biomarkers and Prevention 18(3): 863-865, 2009

Human papillomavirus early gene products and maintenance of the transformed state of cervical cancer cells in vitro. Current Topics in Microbiology and Immunology 144: 175-179, 1989